Allogeneic hematopoietic stem cell transplantations;Allogreffes de cellules souches hématopoïétiques

Transfusion Clinique et Biologique

Volumn 18, Issue 2, 2011, Pages 235-245

  Michallet, M ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Allogeneic transplantation; GVH; Hematopoietic stem cells

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REDUCED INTENSITY CONDITIONING; SHORT SURVEY; STEM CELL MOBILIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BLOOD COMPONENT REMOVAL; BONE MARROW CELLS; COMBINED MODALITY THERAPY; DONOR SELECTION; FEMALE; FETAL BLOOD; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; MYELOABLATIVE AGONISTS; NEOPLASMS; ORGAN PRESERVATION; PLACENTA; PREGNANCY; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 79954632257     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2011.02.021     Document Type: Short Survey

References (84)

1. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
2. Gaugler B., Olive D. Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives. Pathol Biol (Paris) 1998, 46:771-778.
3. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411:385-389.
4. Sullivan K.M., Shulman H.M., Storb R., Weiden P.L., Witherspoon R.P., McDonald G.B., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
5. Blaise D., Olive D., Michallet M., Marit G., Leblond V., Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995, 345:1144-1146.
6. Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J.L., et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias. Lancet 1987, 2:175-178.
7. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
8. Gale R.P., Horowitz M.M., Ash R.C., Champlin R.E., Goldman J.M., Rimm A.A., et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994, 120:646-652.
9. Blaise D., Guyotat D., Reiffers J., Olive D., Michallet M., Bel- langer C., et al. Prospective randomized study of GVHD prevention using an anti-IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT). Bone Marrow Transplant 1991, 7:150.
10. Blaise D., Gravis G., Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1993, 341:51-52.
11. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86:2041-2050.
12. Porter D.L., Connors J.M., Van Deerlin V.M., Duffy K.M., McGarigle C., Saidman S.L., et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999, 17:1234.
13. Ringden O., Labopin M., Gorin N.C., Schmitz N., Schaefer U.W., Pren- tice H.G., et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. Br J Haematol 2000, 111:1130-1137.
14. Michalek J., Collins R.H., Durrani H.P., Vaclavkova P., Ruff L.E., Douek D.C., et al. Definitive separation of graft-versus-leukemia - and graft-versus-host - specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A 2003, 100:1180-1184.
15. Mohty M., Olive D. Can one separate GVH and GVT after allogenic hematopoietic stem cell transplantation?. Med Sci (Paris) 2003, 19:540-541.
16. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000, 28:1197-1205.
17. Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
18. Holler E., Kolb H.J., Mittermuller J., Kaul M., Ledderose G., Duell T., et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995, 86:890-899.
19. Yakoub-Agha I., Mesnil F., Kuentz M., Boiron J.M., Ifrah N., Milpied N., et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French society of bone marrow transplantation and cell therapy. J Clin Oncol 2006, 24:5695-5702.
20. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sut- ton L., et al. Randomized trial of bone marrow versus lenograstim- primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société française de greffe de moelle. J Clin Oncol 2000, 18:537-546.
21. Mohty M., Kuentz M., Michallet M., Bourhis J.H., Milpied N., Sutton L., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002, 100:3128-3134.
22. Gluckman E., Rocha V., Boyer-Chammard A., Locatelli F., Arcese W., Pasquini R., et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997, 337:373-381.
23. Michallet M., Cunha R., Michel G., Socié G., Mohty M., Rio B., et al. Interactions between total nucleated and CD34 cell dose and their impact on outcomes after single and double unrelated cord blood transplantation for patients with hematological malignancies. Blood 2010, 116:361.
24. Ponce D.M., Zheng J., Gonzales A., Lubin M., Heller G., Castro-Malaspina H., et al. Reduced late mortality risk contributes to similar survival after double unit cord blood transplantation as compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011.
25. Rocha V., Labopin M., Ruggeri A., Podestà M., Caballero D., Bonifazi F., et al. Unrelated cord blood transplantation: comparison after single unit cord blood intrabone injection and double unit cord blood transplantation in patients with hematological malignant disorders. A Eurocord-EBMT Analysis. Blood 2010, 116:223.
26. Labussiere H., Le Q.H., Robin M., Fegueux N., Furst S., Mohty M., et al. Double cord blood cell haematopoietic stem cell transplantation after standard or reduced intensity conditioning: report of the SFGM-TC registry. 35th annual meeting of the EBMT 2009. Bone Marrow Transplant 2009, 43:O140.
27. Rocha V., Labopin M., Sanz G., Arcese W., Schwerdtfeger R., Bosi A., et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. N Engl J Med 2004, 351:2276-2285.
28. Brunstein C.G., Gutman J.A., Weisdorf D.J., Woolfrey A.E., Defor T.E., Gooley T.A., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
29. Ruggeri A., Ciceri F., Gluckman E., Labopin M., Rocha V. Eurocord and Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: umbilical cord blood or haplo-identical donors?. Best Pract Res Clin Haematol 2010, 23:207-216.
30. Sorror M., Maris M., Storb R., et al. Hematopoietic cell transplant (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
31. Storb R., Raff R.F., Appelbaum F.R., Deeg H.J., Graham T.C., Schuen- ing F.G., et al. DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. Blood 1994, 84:3558-3566.
32. Spitzer T.R., McAfee S., Sackstein R., Colby C., Toh H.C., Multani P., et al. Intentional induction of mixed chimerism and achievement of antitu- mor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000, 6:309-320.
33. Terenzi A., Aristei C., Aversa F., Perruccio K., Chionne F., Raymondi C., et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996, 28:3101.
34. Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonma- lignant hematologic diseases. Blood 1998, 91:756-763.
35. Sandmaier B.M., McSweeney P., Yu C., Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 2000, 27:78-81.
36. Khouri I.F., Keating M., Korbling M., Przepiorka D., Anderlini P., O'Brien S., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
37. Giralt S., Estey E., Albitar M., Van Besien K., Rondon G., Ander- lini P., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
38. Giralt S., Thall P.F., Khouri I., Wang X., Braunschweig I., Ippolitti C., et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631-637.
39. Childs R., Clave E., Contentin N., Jayasekera D., Hensel N., Leit- man S., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234-3241.
40. Childs R.W. Nonmyeloablative allogeneic peripheral blood stem cell transplantation as immunotherapy for malignant diseases. Cancer J Sci Am 2000, 6:179-187.
41. Kottaridis P.D., Milligan D.W., Chopra R., Chakraverty R.K., Chakra-barti S., Robinson S., et al. In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419-2425.
42. Badros A., Barlogie B., Morris C., Desikan R., Martin S.R., Mun- shi N., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001, 97:2574-2579.
43. Kroger N., Zabelina T., Kruger W., Renges H., Stute N., Durken M., et al. Antithymocyte globulin as part of the preparative regimen prevents graft failure and severe graft-versus-host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001, 80:209-215.
44. Carella A.M., Cavaliere M., Lerma E., Ferrara R., Tedeschi L., Romanelli A., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non Hodgkin's lymphoma. J Clin Oncol 2000, 18:3918-3924.
45. Chakraverty R., Peggs K., Chopra R., Milligan D.W., Kottaridis P.D., Verfuerth S., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002, 99:1071-1078.
46. Martino R., Caballero M.D., Canals C., Simon J.A., Solano C., Urbano-Ispizua A., et al. Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning: results of a prospective multi-centre study. Br J Haematol 2001, 115:653-659.
47. Michallet M., Bilger K., Garban F., Attal M., Huyn A., Blaise D., et al. Allogeneic hematopoietic stem cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and post-transplantation factors on outcome. J Clin Oncol 2001, 19:3340-3349.
48. Mohty M., Faucher C., Vey N., Stoppa A.M., Viret F., Chabbert I., et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000, 26:251-255.
49. Mohty M., Fegueux N., Exbrayat C., Lu Z.Y., Legouffe E., Quittet P., et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001, 28:335-339.
50. McSweeney P.A., Niederwieser D., Shizuru J.A., Sandmaier B.M., Molina A.J., Maloney D.G., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
51. Mohty M., Jacot W., Faucher C., Bay J.O., Zandotti C., Collet L., et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003, 17:2168-2177.
52. Mohty M., Bay J.O., Faucher C., Choufi B., Bilger K., Tournilhac O., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003, 102:470-476.
53. Crocciolo R, Ducastelle, S, Labussière H, Nicolini FE, Thomas X, Barraco F, et al. HLA matching is more critical than CMV matching in predicting non-relapse-mortality of patients undergoing HSCT from an unrelated donor: a retrospective monocenter study. Abstracts of the SFGM-TC congress 2009.
54. Schmid C., Schleuning M., Hentrich M., Markl G.E., Gerbitz A., Tischer J., et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008, 41:721-727.
55. Guglielmi C., Arcese W., Dazzi F., Brand R., Bunjes D., Verdonck LFet al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100:397-405.
56. Brüggemann M., White H., Gaulard P., Garcia-Sanz R., Gameiro P., Oeschger S., et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 concerted action BHM4 CT98-3936. Leukemia 2007, 21:215-221.
57. Schlenk R.F., Döhner K., Krauter J., Fröhling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
58. Lioznov M., El-Cheikh J., Hoffmann F., Hildebrandt Y., Ayuk F., Wolschke C., et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44[+]) and T [HLA-DR(+)] cells. Bone Marrow Transplant 2010, 45:349-353.
59. El-Cheikh J., Michallet M., Nagler A., de Lavallade H., Nicolini F.E., Shimoni A., et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematol 2008, 93:455-458.
60. Kröger N., Shimoni A., Zagrivnaja M., Ayuk F., Lioznov M., Schieder H., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104:3361-3363.
61. Cahn J.Y., Klein J.P., Lee S.J., Milpied N., Blaise D., Antin J.H., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC). Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Société française de greffe de moëlle et therapie cellulaire; Dana Farber Cancer Institute; International Bone Marrow Transplant Registry. Blood 2005, 106:1495-1500.
62. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006, 12:2-8.
63. Takanashi M., Atsuta Y., Fujiwara K., Kodo H., Kai S., Sato H., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010, 116:2839-2846.
64. Holler E., Rogler G., Brenmoehl J., Hahn J., Herfarth H., Greinix H., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006, 107:4189-4193.
65. Mohty M., Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev 2008, 19:53-63.
66. Storb R., Deeg H.J., Whitehead J., Appelbaum F., Beatty P., Bensinger W., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735.
67. Ramsay N.K., Kersey J.H., Robison L.L., McGlave P.B., Woods W.G., Krivit W., et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982, 306:392-397.
68. Storb R., Deeg H.J., Farewell V., Doney K., Appelbaum F., Beatty P. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986, 68:119-125.
69. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987, 1:21-28.
70. Forman S.J., Blume K.G., Krance R.A., Miner P.J., Metter G.E., Hill L.R., et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 1987, 19:2605-2607.
71. Storb R., Deeg H.J., Pepe M., Doney K., Appelbaum F., Beatty P., et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989, 72:567-572.
72. Sullivan K.M., Storb R., Buckner C.D., Fefer A., Fisher L., Weiden P.L., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989, 320:828-834.
73. Storb R., Pepe M., Anasetti C., Appelbaum F.R., Beatty P., Doney K., et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?. Blood 1990, 76:1037-1045.
74. Chao N.J., Schmidt G.M., Niland J.C., Amylon M.D., Dagis A.C., Long G.D., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993, 329:1225-1230.
75. Deeg H.J., Lin D., Leisenring W., Boeckh M., Anasetti C., Appelbaum F.R., et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997, 89:3880-3887.
76. Ratanatharathorn V., Nash R.A., Przepiorka D., Devine S.M., Klein J.L., Weisdorf D., et al. Phase III study comparing methotrexate and tacrolimus (prograf FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
77. Ross M., Schmidt G.M., Niland J.C., Amylon M.D., Dagis A.C., Long G.D., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-versus-host disease: effect on chronic graft-versus-host disease and long-term survival. Biol Blood Marrow Transplant 1999, 5:285-291.
78. Solomon S.R., Mielke S., Savani B.N., Montero A., Wisch L., Childs R., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005, 106:1123-1129.
79. Ribas A., Butterfield L.H., McBride W.H., Dissette V.B., Koh A., Vollmer C.M., et al. Characterization of anti-tumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther 1999, 6:523-536.
80. Khoury H., Trinkaus K., Zhang M.J., Adkins D., Brown R., Vij R., et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 2003, 9:714-721.
81. Mielcarek M., Martin P.J., Leisenring W., Flowers M.E., Maloney D.G., Sandmaier B.M., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
82. Levine J.E., Paczesny S., Mineishi S., Braun T., Choi S.W., Hutchinson R.J., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
83. Filipovich A.H. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:251-257.
84. Shaughnessy P.J., Bolwell B.J., van Besien K., Mistrik M., Grigg A., Dodds A., et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010, 45:1068-1076.